Tagatac, Sulieta B.
HRN: 21-46-04 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/10/2022
CEFTRIAXONE 1G (VIAL)
06/10/2022
06/17/2022
IVT
2 G
Once A Day
UTI
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes